Zydus Lifesciences has informed that it enclosed a copy of press release dated March 21, 2022 titled ‘Zydus receives Prior Approval Supplement (PAS) approval from USFDA for Mycophenolate Mofetil for Injection USP’.
The above information is a part of company’s filings submitted to BSE.